RWA Wealth Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.71M Buy
33,790
+1,643
+5% +$230K 0.05% 167
2025
Q4
$3.95M Buy
32,147
+2,433
+8% +$296K 0.04% 191
2025
Q3
$3.3M Buy
29,714
+556
+2% +$63.2K 0.04% 213
2025
Q2
$3.23M Buy
29,158
+254
+0.9% +$27K 0.04% 198
2025
Q1
$3.24M Sell
28,904
-3,533
-11% -$365K 0.04% 192
2024
Q4
$3M Sell
32,437
-173
-0.5% -$15.6K 0.04% 204
2024
Q3
$2.73M Buy
32,610
+1,290
+4% +$98.4K 0.03% 214
2024
Q2
$2.15M Sell
31,320
-2,175
-6% -$145K 0.03% 228
2024
Q1
$2.45M Buy
33,495
+291
+0.9% +$22.4K 0.03% 212
2023
Q4
$2.69M Buy
33,204
+250
+0.8% +$19.5K 0.04% 197
2023
Q3
$2.47M Sell
32,954
-321
-1% -$24.7K 0.05% 121
2023
Q2
$2.56M Buy
+33,275
New +$2.65M 0.06% 113
2021
Q4
Sell
-3,323
Closed -$232K 256
2021
Q3
$232K Hold
3,323
0.02% 228
2021
Q2
$229K Buy
3,323
+42
+1% +$2.8K 0.02% 228
2021
Q1
$212K Buy
+3,281
New +$212K 0.02% 232
2020
Q4
Sell
-3,352
Closed -$212K 236
2020
Q3
$212K Sell
3,352
-273
-8% -$18.9K 0.02% 202
2020
Q2
$279K Buy
+3,625
New +$278K 0.03% 180
2018
Q3
Sell
-1,214
Closed -$86K 426
2018
Q2
$86K Sell
1,214
-45,813
-97% -$3.24M 0.01% 340
2018
Q1
$3.54M Sell
47,027
-9,252
-16% -$735K 0.46% 54
2017
Q4
$4.03M Sell
56,279
-10,513
-16% -$798K 0.45% 56
2017
Q3
$5.41M Buy
66,792
+1,571
+2% +$120K 0.61% 41
2017
Q2
$4.62M Buy
65,221
+3,114
+5% +$207K 0.57% 47
2017
Q1
$4.22M Buy
+62,107
New +$4.37M 0.55% 49

Other funds holding GILD

RWA Wealth Partners's GILD Position: Q1 2026 in Review

RWA Wealth Partners increased its Gilead Sciences (GILD) stake by 5.1% in Q1 2026, buying an estimated $230K and bringing the position to 33,790 shares worth $4.71M. The position accounts for 0.05% of the portfolio, ranked #167.

RWA Wealth Partners first reported a position in GILD in Q1 2017 and has held it in 23 quarters since. The position peaked at $5.41M in Q3 2017. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • RWA Wealth Partners held 33,790 shares of Gilead Sciences worth $4.71M as of Q1 2026.
  • RWA Wealth Partners bought 1,643 Gilead Sciences shares in Q1 2026, an estimated $230K.
  • Gilead Sciences made up 0.05% of RWA Wealth Partners's portfolio in Q1 2026, its #167 holding.
  • RWA Wealth Partners first reported a position in Gilead Sciences in Q1 2017 and has held it in 23 quarters since.
  • RWA Wealth Partners's Gilead Sciences position peaked at $5.41M in Q3 2017.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on RWA Wealth Partners's 13F filing for Q1 2026, filed 13 May 2026.